Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 4 2023 10 14 296 303 EN Akram Abedi Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Nasrin Namdari Department of Hematology and Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Ahmad Monabati Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Akbar Safaei Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Parvin Rajabi Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Maral Mokhtari Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 2021 01 01 2022 01 18 Myeloid sarcoma (MS) or chloroma is a localized mass composed of blastic cells of granulocytic lineage. It is a subtype of acute myeloid leukemia and usually presents as a complication of acute myeloid leukemia, myeloid dysplastic syndrome, or myeloproliferative disorder. MS occurs in 2.5-9.1% of patients with AML, precedes the clinical disease, coincidence with the onset or at relapse, and in rare conditions, it can occur with no evidence of hematologic disorders. Here, we presented seven cases of MS in unusual locations or with rare presentations at presentation or relapse. We concluded that MS should be considered in the differential diagnosis of any high-grade tumor, especially in a patient with previous history of any myeloid neoplasm. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1515 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1515/1006